Dr. Sandra Gabriela Carias Zuniga, MD

Dr. Carias Zuniga practices at Kaiser Permanente South San Francisco Medical Center in South San Francisco, California, part of Kaiser Permanente.

Dr. Carias Zuniga's NPI, 1114378940, was assigned on June 22, 2016. Dr. Carias Zuniga holds North Carolina license 2020-03838.

Dr. Carias Zuniga's primary practice is Kaiser Permanente South San Francisco Medical Center, at 1200 El Camino Real, South San Francisco, CA 94080 in San Mateo County. The practice phone is (650) 742-3200.

Dr. Carias Zuniga's primary practice is Kaiser Permanente South San Francisco Medical Center in South San Francisco, California, part of Kaiser Permanente. Dr. Carias Zuniga is also affiliated with San Leandro Medical Center. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Carias Zuniga to 1 more hospital, 1 dialysis center, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carias Zuniga practices, 5 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Carias Zuniga's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Carias Zuniga is licensed in North Carolina.

CMS data shows 1,343 Medicare services from Dr. Carias Zuniga across 8 procedure codes in 2024, for 399 Medicare patients. Medicare paid $112,764 for them.

CMS counts 399 Medicare patients who saw Dr. Carias Zuniga in 2024. The largest group is 75 to 84, with 176 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 21% are also on Medicaid. Their average risk score is 3.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carias Zuniga's median patient age at 64, with 39% women.

In 2024, Dr. Carias Zuniga wrote 1,430 Medicare Part D claims for 285 patients. 88% of them were for generic drugs. CMS names the drug for 1,212 of them, across 25 drugs with 11 or more claims each, at $91,206 in total drug cost. In 2023, CMS named 1,165 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Carias Zuniga for performance year 2024, reported as part of a group. Dr. Carias Zuniga accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 135 general payments to Dr. Carias Zuniga from 22 drug and device companies from 2021 to 2024. Food and beverage make up the largest share, 98% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,000.